Gavreto

Active Ingredient(s): Pralsetinib
FDA Approved: * September 4, 2020
Pharm Company: * BLUEPRINT MEDICINES
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Gavreto Overview

Pralsetinib, sold under the brand name Gavreto, is a medication for the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC).[2] Pralsetinib is a tyrosine kinase inhibitor. It is taken by mouth.[2] The most common adverse reactions include increased aspartate aminotransferase (AST), decreased hemoglobin, decreased lymphocytes, decreased neutrophils, increased alanine aminotransferase (ALT), increased creatinine, increased alkaline phos...

Read more Gavreto Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pralsetinib

Recent Gavreto Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pralsetinib
  • Capsule: 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Gavreto: (1 result)

Sorted by National Drug Code
  • 50242-210 Gavreto 100 mg Oral Capsule by Genentech, Inc.

Other drugs which contain Pralsetinib or a similar ingredient: (1 result)